Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Dysregulation of the alternative complement pathway (AP) predisposes individuals to a number of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy. Moreover, glomerular Ig deposits can lead to complement-driven nephropathies. Here we describe the discovery of a highly potent, reversible, and selective small-molecule inhibitor of factor B, a serine protease that drives the central amplification loop of the AP. Oral administration of the inhibitor prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats. In addition, inhibition of factor B prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes. These data demonstrate the potential therapeutic value of using a factor B inhibitor for systemic treatment of complement-mediated diseases and provide a basis for its clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 1×
“It recognizes foreign cell surfaces and induces cell lysis/ killing and inflammatory responses (1, 2).”
BackgroundParoxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
Reynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3928 · Cited by 294
Cited by
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Risitano, A. M., Röth, A., Soret, J., Frieri, C., de Fontbrune, F. S., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Rozenberg, I., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00028-4 · Cited by 110
Self-citationIptacopan in IgA Nephropathy — Final 24-Month Data
Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600743 · Cited by 34
Crowley, M. A., Garland, D. L., Sellner, H., Banks, A., Fan, L., Rejtar, T., Buchanan, N., Delgado, O., Xu, Y. Y., Jose, S., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddac187 · Cited by 20
Self-citationRushing, B., Rohlik, D., Roy, S., Skaff, D., & Garcia, B. (2020) · Molecules · doi:10.3390/molecules25174016 · Cited by 9
Metadata
- Authors
- Schubart, A., Anderson, K., Mainolfi, N., Sellner, H., Ehara, T., Adams, C. M., Mac Sweeney, A., Liao, S.-M., Crowley, M., Littlewood-Evans, A., Sarret, S., Wieczorek, G., Perrot, L., Dubost, V., Flandre, T., Zhang, Y., Smith, R. J. H., Risitano, A. M., Karki, R. G., Zhang, C., Valeur, E., Sirockin, F., Gerhartz, B., Erbel, P., Hughes, N., Smith, T. M., Cumin, F., Argikar, U. A., Haraldsson, B., Mogi, M., Sedrani, R., Wiesmann, C., Jaffee, B., Maibaum, J., Flohr, S., Harrison, R., & Eder, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-03-29
- Volume
- 116
- Issue
- 16
- Pages
- 7926-7931
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2927939151
- Cited by
- 223
- References
- 3
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. https://app.cochat.ai/papers/10.1073/pnas.1820892116
- The paper
- Schubart, A., Anderson, K., Mainolfi, N., Sellner, H., Ehara, T., Adams, C. M., Mac Sweeney, A., Liao, S.-M., Crowley, M., Littlewood-Evans, A., Sarret, S., Wieczorek, G., Perrot, L., Dubost, V., Flandre, T., Zhang, Y., Smith, R. J. H., Risitano, A. M., Karki, R. G., . . . Eder, J. (2019). Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1820892116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.